Major institutional moves, such as Soros Fund Management cutting its stake by nearly 16% in late 2025, signal a lack of confidence in a quick turnaround. The Bull Case: Deep Value and Long-Term Recovery
The primary catalyst for recent stock declines is a "gut punch" from lower .
The company’s net profit margin sat at a razor-thin 0.92% at the end of 2025. Rising medical utilization and relatively flat government reimbursement rates continue to squeeze profitability.
Major institutional moves, such as Soros Fund Management cutting its stake by nearly 16% in late 2025, signal a lack of confidence in a quick turnaround. The Bull Case: Deep Value and Long-Term Recovery
The primary catalyst for recent stock declines is a "gut punch" from lower .
The company’s net profit margin sat at a razor-thin 0.92% at the end of 2025. Rising medical utilization and relatively flat government reimbursement rates continue to squeeze profitability.